Mistletoe therapy for bone cancer

One study on this type of tumour has been conducted, which has been published in various scientific journals under different aspects in 2009 and 2014 [153, 154]. In this study patients with osteosarcoma (disease-free after resected second relapse) received either mistletoe therapy or chemotherapy with etoposide (common at the time) in order to compare whether disease-free survival after 12 month’s observation differed in both groups.

There was a remarkably large difference: In the 9 patients who received mistletoe therapy, it took an average of 39 months (more than three years) for a recurrence of the tumour, and four months in the patients treated with etoposide.

The study included a long-term follow-up of 12 years [287]. The patients in the mistletoe therapy group still showed a significantly longer relapse-free survival time compared to the patients who received oral etoposide.

In the section "Scientific Information" we have presented the results of this study and the long-term follow-up in detail. 

Last update: March 1st, 2023/AT1